[A non-steroidal antirheumatic agent (nabumetone): effectiveness and tolerance in short and long-term use].
Nabumetone, a new nonsteroidal antirheumatic drug (NSAD), is chemically a (6-methoxy-2-naphthyl) butan-2-on. This drug was investigated with regard to its effectiveness and tolerability in an open multicenter study of 3 weeks duration, involving 40 patients with osteo-arthrosis and 45 with rheumatoid arthritis. 11 patients with arthrosis of the hip and 8 suffering from rheumatoid arthritis were continuously treated 6-12 months. The evaluation showed a good result in 85% of the patients with osteo-arthrosis and in 80% of the rheumatoid patients therapy of 3 weeks. Side effects were comparable with those of other NSADs. The changes in laboratory findings were not clinically significant. During long-term therapy both good tolerability and persisting efficacy were evidenced.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002074:Butanones / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006621:Hip Joint / Q000187:drug effects; D006801:Humans; D007719:Knee Joint / Q000187:drug effects; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D000077430:Nabumetone; D010003:Osteoarthritis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D002074:Butanones; D000077430:Nabumetone
Ein neues nichtsteroidales Antirheumatikum (Nabumetone): Wirksamkeit und Verträglichkeit bei Kurz- und Langzeitanwendung.